{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:27:22Z","timestamp":1780514842557,"version":"3.54.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Leukocytoclastic vasculitis (LCV) is a rare, immune-mediated small-vessel vasculitis that can be triggered by infections, autoimmune diseases, or medications, including biologic therapies. We present a case of a patient with Crohn\u2019s disease who developed biopsy proven LCV during longterm infliximab therapy. After four years of sustained remission on infliximab, she developed cutaneous palpable purpura affecting the lower extremities. Laboratory evaluation excluded systemic vasculitis, infection, and other secondary causes. Histopathology confirmed leukocytoclastic vasculitis. Discontinuation of infliximab, led to complete resolution of skin lesions. This case underscores the importance of clinician awareness of rare biologic-associated adverse effects and highlights the need for timely recognition and management to prevent systemic involvement.<\/jats:p>","DOI":"10.1093\/omcr\/omag067","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:35:42Z","timestamp":1774956942000},"source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous Leukocytoclastic Vasculitis as a rare adverse event of infliximab in Crohn\u2019s disease: a case report"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5455-6191","authenticated-orcid":false,"given":"Houssam","family":"EL Mourad","sequence":"first","affiliation":[{"name":"Gastroenterology & Hepatology Department, King Saud University , alyasmmen, street 140, home3-4 Riyadh ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa","family":"Alsayed","sequence":"additional","affiliation":[{"name":"Gastroenterology & Hepatology Department, King Saud University , alyasmmen, street 140, home3-4 Riyadh ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamadar","family":"AL Doheyan","sequence":"additional","affiliation":[{"name":"Pathology Department, King Saud University , Riyadh ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Alomar","sequence":"additional","affiliation":[{"name":"Gastroenterology & Hepatology Department, King Saud University , alyasmmen, street 140, home3-4 Riyadh ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Gastroenterology & Hepatology Department, King Saud University , alyasmmen, street 140, home3-4 Riyadh ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"2026051007065294700_ref1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet (London England)"},{"key":"2026051007065294700_ref2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology."},{"key":"2026051007065294700_ref3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/01.dad.0000181109.54532.c5","article-title":"Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis","volume":"27","author":"Carlson","year":"2005","journal-title":"Am J Dermatopathol"},{"key":"2026051007065294700_ref4","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/jcm12093165","article-title":"Leukocytoclastic Vasculitis secondary to anti-tumor necrosis factor therapy in inflammatory bowel diseases: a Multicenter retrospective cohort study. Journal of","volume":"12","author":"Parra","year":"2023","journal-title":"Clin Med"},{"key":"2026051007065294700_ref5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/01.bor.0000145519.68725.5a","article-title":"Clinical approach to cutaneous vasculitis","volume":"17","author":"Gonzalez-Gay","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"2026051007065294700_ref6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/00002281-199601000-00006","article-title":"Drug-induced vasculitis","volume":"8","author":"Calabrese","year":"1996","journal-title":"Curr Opin Rheumatol"},{"key":"2026051007065294700_ref7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"2026051007065294700_ref8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","article-title":"CRI (Club Rhumatismes et inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France","volume":"73","author":"Saint Marcoux","year":"2006","journal-title":"Joint Bone Spine"},{"key":"2026051007065294700_ref9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2169\/internalmedicine.5340-20","article-title":"Intermittent purpura development associated with Leukocytoclastic Vasculitis induced by infliximab for Crohn's disease","volume":"60","author":"Kishimoto","year":"2021","journal-title":"Intern Med"},{"key":"2026051007065294700_ref10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.gastha.2022.11.007","article-title":"A rare case of Leukocytoclastic Vasculitis associated with infliximab","volume":"2","author":"Wu","year":"2022","journal-title":"Gastro Hep Adv"},{"key":"2026051007065294700_ref11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/1346-8138.14816","article-title":"Ustekinumab for skin reactions associated with anti-tumor necrosis factor-\u03b1 agents in patients with inflammatory bowel diseases: a single-center retrospective study","volume":"46","author":"Ezzedine","year":"2019","journal-title":"J Dermatol"},{"key":"2026051007065294700_ref12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jdcr.2017.06.029","article-title":"Novel posterior auricular cutaneous reaction after anti-TNF-\u03b1 infusion in young women with Crohn's disease","volume":"3","author":"Ko","year":"2017","journal-title":"JAAD Case Rep"},{"key":"2026051007065294700_ref13","doi-asserted-by":"publisher","first-page":"e14883","DOI":"10.1111\/dth.14883","article-title":"Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases","volume":"34","author":"Wu","year":"2021","journal-title":"Dermatol Ther"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2026\/5\/omag067\/68262366\/omag067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2026\/5\/omag067\/68262366\/omag067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:07:00Z","timestamp":1778411220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omag067\/8675259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,9]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omag067","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"omag067"}}